Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 8, 2009, Pages 993-1000

  Emara, Marwan ^a   Cheung, Po Yin ^a   Grabowski, Krzysztof ^b   Sawicki, Grzegorz ^b,c   Wozniak, Mietek ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cancer antigen 19 9 (CA 19 9); Carcino embryonic antigen (CEA); Colorectal cancer; Gastric cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GELATINASE A; GELATINASE B;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER; ZYMOGRAPHY;

AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349514895     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.212     Document Type: Article

References (37)

1. Salamonsen LA. Matrix metalloproteinases and their tissues inhibitor in endocrinology. Trends Endocrinol Metab 1996;7:28-34.
2. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190-196
3. Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003;107:541-550
4. Shin JE, Jung SA, Kim SE, Joo YH, Shim KN, Kim TH, et al. Expression of MMP-2, HIF-1alpha and VEGF in colon adenoma and colon cancer. Korean J Gastroenterol 2007;50:9-18.
5. Miyake K, Shimada M, Nishioka M, Sugimoto K, Batmunkh E, Uto Y, et al. Downregulation of matrix metalloprotease- 9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. Cancer Chemother Pharmacol 2009; Feb 12 wEpub ahead of printx.
6. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001;39:597-602.
7. Bae IH, Yoon SH, Lee SB, Park JK, Ho JN, Um HD. Signaling components involved in Bcl-w-induced migration of gastric cancer cells. Cancer Lett 2008; Dec 19 wEpub ahead of printx.
8. Dragutinovic V, Izrael-Zivković L, Radovanovic N. Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci 2008; Aug 23 wEpub ahead of printx.
9. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17:2253-2258
10. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20:1085-1091
11. Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol 2002,28:24-29
12. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998;58:1395-1399
13. Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ. Gelatinase (MMP-2 and MMP-9) expression in gastrointestinal malignancy. Br J Cancer 1998; 78:1495-1502
14. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/ type IV collagenase) using monoclonal antibodies. Clinica Chimica Acta 1993;221:91-103. (Pubitemid 24022824)
15. Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase- 2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005;11:3046-3050
16. Bazzett LB, Magnus M, Taylor DD, Gercel-Taylor C. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecol Oncol 2003; 90:435-442
17. Makowski GS, Ramsby ML. Calibrating gelatin zymograms with human gelatinase standards. Analytical Biochemistry 1996;236:353-356
18. Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 2004;125:128-140
19. Sternberg SS, editor. Diagnostic surgical pathology. Philadelphia: Lippincott William and Wilkins, 1999.
20. Hossfeld DK, Sherman CD, Love RR, Bosch FX, editors. Manual of clinical oncology. New York: Springer-Verlag, 1990.
21. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994;218:325-329
22. Li L, Zhang S, Lin H, Lin JY. Relationship of expression unbalance of matrix metalloproteinase and tissue inhib- itor of metalloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng 2002;21:305-310
23. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003; 9:899-904.
24. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinaseB/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276:37258-37265
25. Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 1985;260:2493-2500
26. Ferná ndez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix mrtalloproteinase-9/neutrophil gelatinase- associated lipocalin complex plays a role in breast tumor growth and its presence in the urine of breast cancer patients. Clin Cancer Res 2005;11:5390-5395
27. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, Kim JS. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 2005;118:2490-2497
28. Moran A, Iniesta P, Garcia-Aranda C, De Juan C, Diaz- Lopez A, Sanchez-Pernaute A, et al. Clinical relevance of MMP-9, MMP-2, TEMP-1 and TEMP-2 in colorectal cancer. Oncol Rep 2005;13:115-120
29. Zucker S, Lysik RM, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Birkedal-Hansen H, et al. Type IV collagenase/ gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol Biomarkers Prev 1992;1:475-479
30. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338-351
31. Horie Y, Miura K, Matsui K, Yukimasa A, Ohi S, Hamamoto T, et al. Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Cancer 1996;77:1991-1997
32. Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990;85:350-355
33. Nozoe T, Rikimaru T, Mori E, Okuyama T, Takahashi I. Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma. J Surg Oncol 2006;94:132-137
34. Vu TH, Werb Z. Gelatinase B: structure, regulation, and function. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. San Diego: Academic Press, 1998; 115-148
35. Leber MT, Balkwill FR. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gel. Anal Biochem 1997;249:24-28
36. Kleiner DE Jr, Tuuttila A, Tryggvason K, Stetler-Stevenson WG. Stability of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinase- 2 (TIMP-2). Biochemistry 1993;32:1583-1592
37. Petrella BL. Assessment of local proteolytic milieu as a factor in tumor invasiveness and metastasis formation: in vitro collagen degradation and invasion assays. Methods Mol Biol 2009;511:75-84.